Antibodies selective for cells presenting EGFR at high density
US10570211B2 · kind B2 · utility
0Cited by
14References
6Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 20, 2012 |
| Grant date | Feb 25, 2020 |
| Priority date | — |
| Expiry date | Jan 20, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/567
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Herein described are antibodies to epidermal growth factor receptor (EGFR) having an EGFR binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.